查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405902

反義和 RNAi 療法市場規模、佔有率和趨勢分析報告：按技術、按應用、按給藥途徑、按地區和細分市場預測，2024-2030 年

Antisense & RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular Disorder, Genetic Disorder), By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

反義和 RNAi 療法市場成長和趨勢：

Grand View Research, Inc.最新報告預測，到2030年，全球反義和RNAi治療市場規模將達到146.6億美元，2024年至2030年複合年成長率為18.12%。

增加對臨床研究的資助，包括生物載體和奈米技術的開拓以及新藥物分子的推出，對於產品開發至關重要，也是市場擴張的驅動力。

跨國醫療保健組織提高人們對各種疾病的認知並支持新治療方法的開發。參與支持研究機構的臨床試驗的私人公司預計也將成為該領域擴張的主要推動力。例如，2022 年 3 月，Biogen Inc. 和 Ionis Pharmaceuticals, Inc. 宣布了一項臨床實驗反義寡核苷酸的 1 期試驗結果，該試驗用於治療肌萎縮側索硬化症 (ALS) 患者。隨著基於反義和 RNAi 療法的產品推出數量的增加，市場參與企業增加此類臨床試驗預計將推動市場成長。

反義和RNAi療法會影響細胞的生長週期，可用於治療多種針對核酸的疾病。 miRNA 再生基因表現和控制蛋白質生產的能力引起了人們的廣泛關注，從而對工業進步產生了影響。根據美國科學促進會 2023 年 7 月發表的一篇論文，麻省大學陳醫學院和 RUSH 大學醫學中心開發的一種反義療法可抑制X染色體脆折症候群患者細胞標本中一種名為FMRP 的蛋白質的產生.結果證明對恢復很有用。預計該行業的此類進步將在預測期內推動對用於治療多種疾病的 RNAi 和反義核酸治療藥物的需求。

反義和 RNAi 治療市場報告亮點

  • 反義RNA技術因其在神經退化性疾病和遺傳性疾病等疾病的廣泛應用，在2023年佔據該技術領域最大的收益佔有率。
  • RNA干擾領域預計將成為成長最快的技術領域。此技術又分為siRNA和miRNA。 miRNA 在維持細胞身份方面發揮關鍵作用，因此被用來更好地了解癌症擴散。
  • 從應用來看，遺傳疾病領域佔據主導地位，主要參與者越來越注重開發新型遺傳疾病治療方法。
  • 北美佔據全球反義和RNAi治療市場最大的銷售佔有率。該地區的主導地位是由於該地區存在多個正在努力加強其行業地位的參與者。
  • 隨著 Secarna 等主要企業在該地區營運和擴張，預計歐洲將在 2024 年至 2030 年的預測期內實現最快的成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章反義和 RNAi 治療市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 反義和 RNAi 治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章反義和RNAi治療藥物市場：技術評估和趨勢分析

  • 2023年及2030年技術市場佔有率
  • 細分儀表板
  • 按技術展望分類的全球反義和 RNAi 治療市場
  • 2018年至2030年市場規模、預測與趨勢分析如下
    • RNA干擾
    • 反義RNA

第5章反義和RNAi治療藥物市場：應用估算和趨勢分析

  • 2023年及2030年應用市場佔有率
  • 細分儀表板
  • 全球反義和 RNAi 治療市場按應用前景展望
  • 2018年至2030年市場規模、預測與趨勢分析如下
    • 眼科
    • 心臟代謝和腎臟疾病
    • 呼吸系統疾病
    • 癌症
    • 神經退化性疾病
    • 遺傳疾病
    • 感染疾病
    • 皮膚病
    • 其他

第6章反義與RNAi治療藥物市場：給藥途徑估算與趨勢分析

  • 2023 年及 2030 年給藥途徑市場佔有率
  • 細分儀表板
  • 按給藥途徑分類的全球反義和 RNAi 療法市場前景
  • 2018年至2030年市場規模、預測與趨勢分析如下
    • 靜脈注射
    • 鞘內注射
    • 皮下注射
    • 其他

第7章反義和RNAi治療藥物市場：區域估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭分類
  • 供應商形勢
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023 年主要企業股票分析
    • Olix Pharmaceuticals
    • GSK plc
    • Sanofi
    • Alnylam Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Benitec Biopharma Inc
    • Silence Therapeutics
    • Arbutus Biopharma
    • Bio-Path Holdings Inc
    • Antisense Therapeutics Limited.
Product Code: 978-1-68038-805-3

Antisense & RNAi Therapeutics Market Growth & Trends:

The global antisense & RNAi therapeutics market size is expected to reach USD 14.66 billion by 2030, registering a CAGR of 18.12% from 2024 to 2030, according to a new report by Grand View Research, Inc. Developments in biological vectors & nanotechnology and increased financial help for clinical investigations, including the launch of novel drug molecules, are critical in product development and are driving market expansion.

Multinational healthcare organizations raise awareness and assist in the development of novel remedies for a variety of ailments. Private institutes and companies participating in conducting trials through supporting research institutes are predicted to considerably fuel sector expansion. For instance, in March 2022, Biogen Inc. and Ionis Pharmaceuticals, Inc. announced outcomes from the Phase 1 study of an investigational antisense oligonucleotide for treating people with amyotrophic lateral sclerosis (ALS). Such increasing clinical trials through industry participants is anticipated to propel the market growth by rising the product launches based on antisense and RNAi therapies.

Antisense and RNAi therapies can be used to treat various disorders that impact the cell growth cycle and target nucleic acids. The ability of miRNA to regenerate gene expression and regulate protein production, consequently impacting industrial advancement, is receiving much attention. According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome. Such advancements in the industry are expected to propel the demand for RNAi and antisense therapeutics for treating numerous diseases over the forecast period.

Antisense & RNAi Therapeutics Market Report Highlights:

  • Antisense RNA technology accounted for the largest revenue share in 2023 in the technology segment due to its wide applications in diseases like neurodegenerative and genetic conditions.
  • The RNA interference segment is anticipated to witness the fastest growth in technology. This technology is further segmented into siRNA & miRNA. Due to miRNA's important role in sustaining cell identity, it's being employed to understand cancer spread better.
  • Based on application, the genetic disease segment's dominance can be attributed to key players' increasing focus on developing novel genetic disease treatments.
  • North America accounted for the largest revenue share in the global antisense and RNAi therapeutics market. The region's dominance can be attributed to the presence of several players in the region and their efforts to strengthen their position in the industry.
  • Europe is anticipated to register the fastest growth over the forecast period from 2024 to 2030, owing to key companies like Secarna operating and expanding in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Route of Administration outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antisense & RNAi Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Presence of strong pipeline product portfolio
      • 3.2.1.2. Introduction of technological advancements in drug delivery
      • 3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises
      • 3.2.1.4. Rising collaborations between pharmaceutical companies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Expensive and tedious research programs
      • 3.2.2.2. Delivery of RNAi therapeutics and off-target effects
  • 3.3. Antisense & RNAi Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Antisense & RNAi Therapeutics Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Antisense & RNAi Therapeutics Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. RNA Interference
      • 4.4.1.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Antisense RNA
      • 4.4.2.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antisense & RNAi Therapeutics Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Antisense & RNAi Therapeutics Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Ocular
      • 5.4.1.1. Ocular Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Cardio metabolic & Renal Disorders
      • 5.4.2.1. Cardio metabolic & Renal Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Respiratory Disorders
      • 5.4.3.1. Respiratory Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Cancer
      • 5.4.4.1. Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. Neurodegenerative Disorders
      • 5.4.5.1. Neurodegenerative Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.6. Genetic Disorders
      • 5.4.6.1. Genetic Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.7. Infectious Diseases
      • 5.4.7.1. Infectious Diseases Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.8. Skin Diseases
      • 5.4.8.1. Skin Diseases Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.9. Others
      • 5.4.9.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antisense & RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Antisense & RNAi Therapeutics Market, by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Intravenous Injections
      • 6.4.1.1. Intravenous Injections Market estimates and forecasts, 2018 to 2030 (USD million)
    • 6.4.2. Intrathecal Injections
      • 6.4.2.1. Intrathecal Injections Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.3. Subcutaneous Injections
      • 6.4.3.1. Subcutaneous Injections Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Antisense & RNAi Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Target disease prevalence
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Competitive scenario
      • 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Target disease prevalence
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Competitive scenario
      • 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Target disease prevalence
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Competitive scenario
      • 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Target disease prevalence
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Competitive scenario
      • 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Target disease prevalence
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Competitive scenario
      • 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Target disease prevalence
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Competitive scenario
      • 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Target disease prevalence
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Competitive scenario
      • 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Target disease prevalence
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Competitive scenario
      • 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Target disease prevalence
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Competitive scenario
      • 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Target disease prevalence
      • 7.6.8.3. Regulatory framework
      • 7.6.8.4. Competitive scenario
      • 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Target disease prevalence
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Competitive scenario
      • 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Target disease prevalence
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Competitive scenario
      • 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Target disease prevalence
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Competitive scenario
      • 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Target disease prevalence
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Competitive scenario
      • 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Target disease prevalence
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Competitive scenario
      • 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Target disease prevalence
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Competitive scenario
      • 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Target disease prevalence
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Competitive scenario
      • 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Target disease prevalence
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Competitive scenario
      • 7.8.2.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Target disease prevalence
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Competitive scenario
      • 7.8.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Target disease prevalence
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. Competitive scenario
      • 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Target disease prevalence
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Competitive scenario
      • 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Target disease prevalence
      • 7.9.3.3. Regulatory framework
      • 7.9.3.4. Competitive scenario
      • 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Target disease prevalence
      • 7.9.4.3. Regulatory framework
      • 7.9.4.4. Competitive scenario
      • 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Olix Pharmaceuticals
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GSK plc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Sanofi
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Alnylam Pharmaceuticals, Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Ionis Pharmaceuticals, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Benitec Biopharma Inc
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Silence Therapeutics
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Arbutus Biopharma
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Bio-Path Holdings Inc
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Antisense Therapeutics Limited.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 7 U.S. antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 10 Canada antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 14 Europe antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 17 Germany antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Germany antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 20 UK antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 UK antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 22 France antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 23 France antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 France antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 26 Italy antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Italy antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 29 Spain antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Spain antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 32 Denmark antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Denmark antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 35 Sweden antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Sweden antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 38 Norway antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Norway antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 44 China antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 45 China antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 China antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 48 Japan antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 Japan antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 50 India antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 51 India antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 India antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 54 South Korea antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 South Korea antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Australia antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 58 Australia antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 60 Thailand antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Thailand antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 63 Latin America antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Latin America surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 66 Latin America percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 69 Brazil antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 72 Mexico antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Mexico surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 75 Argentina antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Argentina surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 78 MEA antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 79 MEA antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 MEA antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 82 South Africa antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 South Africa antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 88 UAE antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 UAE antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 91 Kuwait antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 Kuwait antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in Asia Pacific
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in Middle East Africa
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antisense & RNAi therapeutics market: market outlook
  • Fig. 14 Antisense & RNAi therapeutics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antisense & RNAi therapeutics market driver impact
  • Fig. 20 Antisense & RNAi therapeutics market restraint impact
  • Fig. 21 Antisense & RNAi therapeutics market strategic initiatives analysis
  • Fig. 22 Antisense & RNAi therapeutics market: Technology movement analysis
  • Fig. 23 Antisense & RNAi therapeutics market: Technology outlook and key takeaways
  • Fig. 24 RNA Interference market estimates and forecast, 2018 - 2030
  • Fig. 25 Antisense RNA estimates and forecast, 2018 - 2030
  • Fig. 26 Antisense & RNAi therapeutics Market: Route of administration movement analysis
  • Fig. 27 Antisense & RNAi therapeutics market: Route of administration outlook and key takeaways
  • Fig. 28 Intravenous injections market estimates and forecasts, 2018 - 2030
  • Fig. 29 Intrathecal injections market estimates and forecasts, 2018 - 2030
  • Fig. 30 Subcutaneous injections market estimates and forecasts, 2018 - 2030
  • Fig. 31 Other delivery methods market estimates and forecasts, 2018 - 2030
  • Fig. 32 Antisense & RNAi therapeutics market: application movement analysis
  • Fig. 33 Antisense & RNAi therapeutics market: application outlook and key takeaways
  • Fig. 34 Genetic disease market estimates and forecasts, 2018 - 2030
  • Fig. 35 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 36 Infectious disease market estimates and forecasts, 2018 - 2030
  • Fig. 37 Neurodegenerative disorders market estimates and forecasts, 2018 - 2030
  • Fig. 38 Cardiometabolic & renal disorders market estimates and forecasts, 2018 - 2030
  • Fig. 39 Ocular disorders market estimates and forecasts, 2018 - 2030
  • Fig. 40 Respiratory disorders market estimates and forecasts, 2018 - 2030
  • Fig. 41 Skin disorders market estimates and forecasts, 2018 - 2030
  • Fig. 42 Others market estimates and forecasts, 2018 - 2030
  • Fig. 43 Global antisense & RNAi therapeutics market: Regional movement analysis
  • Fig. 44 Global antisense & RNAi therapeutics market: Regional outlook and key takeaways
  • Fig. 45 Global antisense & RNAi therapeutics market share and leading players
  • Fig. 46 North America market share and leading players
  • Fig. 47 Europe market share and leading players
  • Fig. 48 Asia Pacific market share and leading players
  • Fig. 49 Latin America market share and leading players
  • Fig. 50 Middle East & Africa market share and leading players
  • Fig. 51 North America
  • Fig. 52 North America market estimates and forecasts, 2018 - 2030
  • Fig. 53 U.S.
  • Fig. 54 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 57 Europe
  • Fig. 58 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 59 UK
  • Fig. 60 UK market estimates and forecasts, 2018 - 2030
  • Fig. 61 Germany
  • Fig. 62 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 63 France
  • Fig. 64 France market estimates and forecasts, 2018 - 2030
  • Fig. 65 Italy
  • Fig. 66 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 67 Spain
  • Fig. 68 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 69 Denmark
  • Fig. 70 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 71 Sweden
  • Fig. 72 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 73 Norway
  • Fig. 74 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 75 Asia Pacific
  • Fig. 76 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 77 China
  • Fig. 78 China market estimates and forecasts, 2018 - 2030
  • Fig. 79 Japan
  • Fig. 80 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 81 India
  • Fig. 82 India market estimates and forecasts, 2018 - 2030
  • Fig. 83 Thailand
  • Fig. 84 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 85 South Korea
  • Fig. 86 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 87 Australia
  • Fig. 88 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 89 Latin America
  • Fig. 90 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 91 Brazil
  • Fig. 92 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 93 Mexico
  • Fig. 94 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 97 Middle East and Africa
  • Fig. 98 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 107 Market share of key market players- Antisense & RNAi therapeutics market